MBX Biosciences, Inc.
MBX Nasdaq Pharmaceutical Preparations Financials FY2023–FY2025
Last close · Oct 23, 2026
$48.50
3.9%What MBX Biosciences, Inc. does
No business description yet.
- Legal name
- MBX Biosciences, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Accession · CIK
- 0001193125-26-103121
0001776111
Revenue and margins
MBX Biosciences, Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$81.9M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
MBX Biosciences, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 243.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably MBX Biosciences, Inc. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $80.7M | $262M | $374M |
| Current ratio | 21.3x | 24.2x | 24.6x |
| Quick ratio | 21.3x | 24.2x | 24.6x |
| Total assets | $84.2M | $269M | $385M |
| Total liabilities | $4.3M | $11.1M | $15.9M |
| Shareholders' equity | −$72.5M | $257M | $369M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✓ | ✓ |
| Share count didn't rise | — | ✕ | ✕ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 6 | — / 6 |
| Accruals ratio | −0.7% | −4.1% | −2.2% |
| Altman Z'' | −17.28 | 27.25 | 26.97 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Research and development | $28.5M | $57.4M | $79.2M |
| Operating income | −$35.3M | −$68.2M | −$98.1M |
| Pretax income | — | −$61.9M | −$87.0M |
| Income tax | $0.0M | $0.0M | $0.0M |
| Net income | −$32.6M | −$61.9M | −$87.0M |
| Net income to common | −$32.6M | −$61.9M | −$87.0M |
| Diluted EPS | −$31.96 | −$5.82 | −$2.38 |
| Diluted shares | 0.00B | 0.01B | 0.04B |
| Cash flow | |||
| Cash from operations | −$32.0M | −$54.7M | −$79.9M |
| Capital expenditure | $0.1M | $0.9M | $1.9M |
| Free cash flow | −$32.1M | −$55.6M | −$81.9M |
| Depreciation and amortization | $0.2M | $0.2M | $0.2M |
| Stock-based compensation | $2.0M | $5.2M | $8.7M |
| Balance sheet | |||
| Cash and short-term investments | $80.7M | $262M | $374M |
| Current assets | $83.5M | $267M | $382M |
| Current liabilities | $3.9M | $11.1M | $15.5M |
| Property and equipment, net | $0.4M | $1.1M | $2.7M |
| Total assets | $84.2M | $269M | $385M |
| Total liabilities | $4.3M | $11.1M | $15.9M |
| Preferred stock | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | −$72.5M | $257M | $369M |
| Returns | |||
| Return on capital employed | −44.0% | −26.5% | −26.5% |
| Return on equity | — | −67.0% | −27.8% |
| Return on assets | −38.7% | −35.1% | −26.6% |
| Return on tangible equity | — | −24.1% | −23.6% |
| Growth | |||
| Share count change | — | 944.7% | 243.0% |
| Financial health | |||
| Current ratio | 21.3x | 24.2x | 24.6x |
| Quick ratio | 21.3x | 24.2x | 24.6x |
| Quality scores | |||
| Altman Z'' | −17.3 | 27.3 | 27.0 |
| Accruals ratio | −0.7% | −4.1% | −2.2% |
Source: SEC EDGAR XBRL filings (CIK 0001776111). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.